UVA Health CEO steps down following internal investigation

The CEO and executive vice president for health affairs at the University of Virginia (UVA) Health has stepped down after five years in the role.

The academic health system announced that Craig Kent was leaving his position but did not provide further comment. However, his resignation follows a letter of no confidence signed by 128 members of the UVA faculty in September. The signees cited a myriad of issues, ranging from worsening patient safety to questionable hiring decisions.

The letter also implicated the dean of UVA School of Medicine, Melina Kibbe, MD. At the time, the president of UVA defended Kent and Kibbe, seemingly brushing off the letter. In his response, he wrote that it was “difficult to believe that the right answer here is to force yet another change in leadership.”

However, a law firm was hired to investigate the accusations made by staff. The results of that investigation were revealed during an internal meeting on Tuesday. Soon after, Kent resigned from his executive role.

Mitch Rosner, MD, a nephrologist at UVA Health, has stepped in as acting executive VP for health affairs in the interim while the institution seeks a permanent replacement.

UVA has declined media requests to comment further on the change.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The Outsourcing Facilities Association, a Texas-based trade group, is alleging that supply issues still remain for Ozempic and Wegovy. The group believes the FDA has ignored those issues.

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.